Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -26.97% is 73% above its 5-year average of -100.75%, near the high end of its 5-year range (-238.03%–-13.84%).
20.08% above its 12-month average of -33.75%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -27.08%.
NET PROFIT MARGIN
-26.97%
NET PROFIT MARGIN AVG TTM
-33.75%
NET PROFIT MARGIN AVG 3Y
-51.92%
NET PROFIT MARGIN AVG 5Y
-100.75%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+20.08%
CURRENT VS 3Y AVG
+48.06%
CURRENT VS 5Y AVG
+73.23%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.26%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-10273.08%
vs the sector median at left
Biodesix, Inc.
Market Cap
$227.60M
Net Profit Margin
-26.97%
TTM Avg
-33.75%
3Y Avg
-51.92%
5Y Avg
-100.75%
Market Cap
$229.46M
Net Profit Margin
-8.70%
TTM Avg
-47.52%
3Y Avg
-47.68%
5Y Avg
-98.44%
Market Cap
$230.79M
Net Profit Margin
-912.25%
TTM Avg
-448.06%
3Y Avg
-224.03%
5Y Avg
-224.03%
Market Cap
$222.74M
Net Profit Margin
-171.72%
TTM Avg
-262.44%
3Y Avg
-337.71%
5Y Avg
-348.92%
Market Cap
$222.26M
Net Profit Margin
-553.88%
TTM Avg
-2620.95%
3Y Avg
-26640.28%
5Y Avg
-17808.90%
Market Cap
$233.46M
Net Profit Margin
-155582.08%
TTM Avg
-91683.52%
3Y Avg
-62749.43%
5Y Avg
-41832.95%
Market Cap
$234.90M
Net Profit Margin
-5.14%
TTM Avg
33.66%
3Y Avg
36.64%
5Y Avg
40.60%
Market Cap
$235.36M
Net Profit Margin
-29747.89%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Biodesix, Inc. (BDSX) | $227.60M | -26.97% | -33.75% | -51.92% | -100.75% |
| Vogenx Inc. (VOGX)vs › | $226.73M | N/A | N/A | N/A | N/A |
| MacroGenics, Inc. (MGNX)vs › | $229.46M | -8.70% | -47.52% | -47.68% | -98.44% |
| BioAge Labs Inc. (BIOA)vs › | $230.79M | -912.25% | -448.06% | -224.03% | -224.03% |
| Profound Medical Corp. (PROF)vs › | $222.74M | -171.72% | -262.44% | -337.71% | -348.92% |
| Keros Therapeutics, Inc. (KROS)vs › | $222.26M | -553.88% | -2620.95% | -26640.28% | -17808.90% |
| InflaRx N.V. (IFRX)vs › | $233.46M | -155582.08% | -91683.52% | -62749.43% | -41832.95% |
| SIGA Technologies, Inc. (SIGA)vs › | $234.90M | -5.14% | 33.66% | 36.64% | 40.60% |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $235.36M | -29747.89% | 0.00% | 0.00% | 0.00% |
| Utah Medical Products, Inc. (UTMD)vs › | $235.40M | 29.04% | 31.61% | 31.96% | 30.60% |
Operating Margin
-31.4%
Net Profit Margin
-27.0%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -27.08% |
| 2026-03-31 | -30.50% |
| 2025-12-31 | -13.84% |
| 2025-09-30 | -40.04% |
| 2025-06-30 | -57.29% |
| 2025-03-31 | -61.82% |
| 2024-12-31 | -40.39% |
| 2024-09-30 | -56.51% |
| 2024-06-30 | -60.30% |
| 2024-03-31 | -91.87% |
| 2023-12-31 | -62.31% |
| 2023-09-30 | -81.16% |
| 2023-06-30 | -112.50% |
| 2023-03-31 | -206.52% |
| 2022-12-31 | -211.70% |
| 2022-09-30 | -123.34% |
| 2022-06-30 | -144.51% |
| 2022-03-31 | -238.03% |
| 2021-12-31 | -183.86% |
| 2021-09-30 | -176.30% |
| 2021-06-30 | -95.94% |
| 2021-03-31 | -24.11% |
| 2020-12-31 | -16.77% |
| 2020-09-30 | -96.21% |
| 2020-06-30 | -195.00% |
| 2020-03-31 | -190.44% |
| 2019-12-31 | -78.89% |
| 2019-09-30 | -243.56% |
| 2019-06-30 | -118.32% |
| 2019-03-31 | -118.32% |
| 2018-06-30 | -128.06% |
| 2018-03-31 | -128.06% |
